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Summary 
Background Many randomised controlled trials have investigated the eﬀ ect of adjuvant chemotherapy in operable 
non-small-cell lung cancer. We undertook two comprehensive systematic reviews and meta-analyses to establish the 
eﬀ ects of adding adjuvant chemotherapy to surgery, or to surgery plus radiotherapy. 
Methods We included randomised trials, not confounded by additional therapeutic diﬀ erences between the two 
groups and that started randomisation on or after Jan 1, 1965, which compared surgery plus adjuvant chemotherapy 
versus surgery alone, or surgery plus adjuvant radiotherapy and chemotherapy versus surgery plus adjuvant 
radiotherapy. Updated individual patient data were collected, checked, and included in meta-analyses stratiﬁ ed by 
trial. The primary endpoint was overall survival, deﬁ ned as time from randomisation until death by any cause. All 
analyses were by intention to treat. 
Findings The ﬁ rst meta-analysis of surgery plus chemotherapy versus surgery alone was based on 34 trial comparisons 
and 8447 patients (3323 deaths). We recorded a beneﬁ t of adding chemotherapy after surgery (hazard ratio [HR] 0·86, 
95% CI 0·81–0·92, p<0·0001), with an absolute increase in survival of 4% (95% CI 3–6) at 5 years (from 60% to 64%). 
The second meta-analysis of surgery plus radiotherapy and chemotherapy versus surgery plus radiotherapy was based 
on 13 trial comparisons and 2660 patients (1909 deaths). We recorded a beneﬁ t of adding chemotherapy to surgery 
plus radiotherapy (HR 0·88, 95% CI 0·81–0·97, p=0·009), representing an absolute improvement in survival of 4% 
(95% CI 1–8) at 5 years (from 29% to 33%). In both meta-analyses we noted little variation in eﬀ ect according to the 
type of chemotherapy, other trial characteristics, or patient subgroup. 
Interpretation The addition of adjuvant chemotherapy after surgery for patients with operable non-small-cell lung 
cancer improves survival, irrespective of whether chemotherapy was adjuvant to surgery alone or adjuvant to surgery 
plus radiotherapy. 
Funding UK Medical Research Council, Institut Gustave-Roussy, Programme Hospitalier de Recherche Clinique 
(AOM 05 209), Ligue Nationale Contre le Cancer, and Sanoﬁ -Aventis. 
Introduction
Around 1·5 million new cases of lung cancer are 
diagnosed every year,1 and about 85% of tumours are 
non-small-cell lung cancer.2 Although surgery is regarded 
as the best possible treatment, only 20–25% of tumours 
are suitable for potentially curative resection.3
Our previous meta-analyses of individual patient 
data4 provided evidence that cisplatin-based chemo-
therapy after surgery might increase survival (hazard 
ratio [HR] 0·87, 95% CI 0·74–1·02, p=0·08). With 
fewer trials and patients, the value of chemotherapy 
after surgery plus postoperative radiotherapy was less 
clear in our previous meta-analyses.4 Meta-analyses5–10 
showing signiﬁ cant survival beneﬁ ts with adjuvant 
chemotherapy have included many trials and patients 
(webappendix p 1). We aimed to assess the eﬀ ects of 
adjuvant chemotherapy, with or without postoperative 
radiotherapy, in two new comprehensive meta-analyses 
of individual patient data. By comparison with our 
previous meta-analyses, this study was restricted to 
patients with early stage disease. 
Methods
Study design, search strategy, and study selection
Before data collection, two protocols were developed: one 
for the meta-analysis of chemotherapy plus surgery and 
the other for the meta-analysis of chemotherapy plus 
surgery and radiotherapy. 
To be included, trials had to be randomised, not con-
founded by additional therapeutic diﬀ erences between the 
two groups, and have started randomisation on or after 
Jan 1, 1965. Trials should have aimed to include patients 
who had undergone a potentially curative resection and not 
received previous chemotherapy. For the ﬁ rst meta-analysis, 
trials should have compared surgery plus adjuvant chemo-
therapy versus surgery alone. For the second, trials should 
have compared surgery plus adjuvant radiotherapy and 
chemotherapy versus surgery plus adjuvant radiotherapy. 
We excluded trials using long-term alkylating agents for 
more than 1 year, because these agents are no longer used 
to treat non-small-cell lung cancer and are harmful.4
To limit publication bias, we included published and 
unpublished trials with no restriction by language. 
See Online for webappendix
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Searches of Medline and CancerLit (with an amended 
version of the Cochrane Collaboration optimal search 
strategy11) and trial registers, with additional MESH and 
free text terms for non-small-cell lung cancer and 
chemotherapy, were supplemented by hand searches of 
conference proceedings and reference lists of trial 
publications and review articles. Our collaborators were 
asked whether they knew of additional trials. Initial 
searches were undertaken in 2003 and were regularly 
updated until September, 2009.
Data collection
For the 15 trials included in our previous meta-analysis 
undertaken in 1995, we sought only updated follow-up. 
For new trials, we gathered data for age, sex, extent of 
resection, pathological tumour stage, histology, per-
formance status, treatment group, date of randomisation, 
recurrence, survival, and follow-up for all patients 
randomly assigned.  
We used standard checks to identify missing data, 
assess data validity, and consistency. We veriﬁ ed the 
amount of missing data, checked the order of dates, 
and assessed data validity and consistency. To assess 
randomisation integrity, we checked patterns of 
treatment allocation and balance of baseline 
characteristics by treatment group. Follow-up of sur-
viving patients was checked to ensure that it was 
balanced by treatment group and was up-to-date. Any 
queries were resolved and the ﬁ nal database veriﬁ ed by 
each trial investigator or statistician
Deﬁ nition of outcome measures
The primary outcome of overall survival was deﬁ ned as 
the time from randomisation until death by any cause. 
Living patients were censored on the date of last follow-
up. Recurrence-free survival, a secondary outcome, was 
deﬁ ned as the time from randomisation until ﬁ rst 
recurrence or death by any cause. Patients alive without 
disease were censored on the date of last follow-up. To 
avoid bias from under-reporting of subsequent events, 
time to locoregional recurrence was deﬁ ned as the time 
from randomisation until ﬁ rst locoregional recurrence, 
and patients with previous distant recurrences were 
censored at the time of distant recurrence. Similarly, for 
time to distant recurrence, patients with previous 
locoregional recurrences were censored on that date.
Statistical analysis
Unless otherwise stated, all analyses were prespeciﬁ ed in 
the protocols, and undertaken on an intention-to-treat 
Years of 
accrual
Number of 
patients
Country Drug used (dose per cycle [mg/m²]) Number of cycles Stage Extent of 
resection
Without tegafur and uracil/tegafur
Platinum+vinca alkaloid/etoposide
IPCR Chiba28 1985–91 29 Japan Cisplatin (80), vindesine (3), mitomycin (8) >2 NK Complete and 
incomplete
JLCSSG31 1986–88 209 Japan Cisplatin (80), vindesine (6) 2–3 III NK
Mineo36 1988–94 66 Italy Cisplatin (100), etoposide (120) 6 IB Complete
Park141 1989–98 118 South Korea Cisplatin (100), mitomycin (10), vinblastine (6) 3–4 I Complete
Park243 1989–98 108 South Korea Cisplatin (100), mitomycin (10), vinblastine (6) 3–4 IIIA Complete
ALPI116 1994–99 618* European Cisplatin (100), vindesine (6), mitomycin (8) 3 I–IIIA Complete
IALT118 1995–2001 1001* International Cisplatin (80, 100, or 120) and vindesine (3; weekly then twice weekly); 
or vinblastine (8; weekly then twice weekly) or etoposide (300)
3 or 4 I–III Complete
BLT119 1995–2001 136* International Cisplatin (50), mitomycin (6), vinblastine (6); or cisplatin (80), 
vindesine (6) 
3 I–III Complete
JCOG 930439 1994–99 119 Japan Cisplatin (80), vindesine (3) 3 I–III Complete and 
incomplete
Platinum+vinorelbine
ANITA117 1994–2000 463* International Cisplatin (100), vinorelbine (120) 4 IB–IIIA Complete
JBR.1042 1994–2001 482 Canada, USA Cisplatin (50), vinorelbine (25; initial patients received 30) 4 IB–II Complete
IALT218 1995–2001 294* International Cisplatin (80, 100, or 120), vinorelbine (30; weekly) 3 or 4 I–III Complete
BLT219 1995–2001 65* International Cisplatin (80), vinorelbine (60) 3 I–III Complete
Platinum+taxane
CALGB 963344 1996–2003 344 USA Carboplatin (6 mg/mL over 45–60 min), paclitaxel (200) 4 IB Complete
Other platinum regimens
LCSG 80130 1980–86 283 USA, Canada Cisplatin (60), doxorubicin (40), cyclophosphamide (400) 4 I Complete
FLCSG145 1980–86 110 Finland Cisplatin (40), doxorubicin (40), cyclophosphamide (400) 6 I–III NK
LCSG 85332 1985–89 188 USA, Canada Cisplatin (60), doxorubicin (40), cyclophosphamide (400) 4 II–III Complete
BLT319 1995–2001 118* International Cisplatin (50), mitomycin (6), ifosphamide (3) 3 I–III Complete
(Continues on next page)
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basis. For every outcome, we used the log-rank expected 
number of events and variance to calculate individual 
trial HRs, which were pooled across trials with the ﬁ xed-
eﬀ ect model. Survival is also presented with simple 
(non-stratiﬁ ed) Kaplan-Meier curves. We calculated the 
median follow-up for all patients with the reverse 
Kaplan-Meier method.12
For survival, to explore any eﬀ ect of trial and patient 
characteristics on the eﬀ ect of chemotherapy, pooled 
HRs were calculated for every prespeciﬁ ed trial group or 
patient subgroup. We used χ² tests for interaction to 
investigate diﬀ erences in the treatment eﬀ ect across trial 
groups. To investigate diﬀ erences in the treatment eﬀ ect 
across patient subgroups, we undertook Cox regressions 
including the relevant treatment by subgroup interaction 
term within trials and the interaction coeﬃ  cients (HRs) 
pooled across trials. χ² tests and the I² statistic were used 
to assess heterogeneity in the treatment eﬀ ect or patient 
subgroup interactions across trials. 
We calculated absolute diﬀ erences in overall survival 
at 5 years using overall HRs and survival in the control 
group. If a diﬀ erence in eﬀ ect by trial group or patient 
subgroup was identiﬁ ed, we used HRs and control group 
survival for the relevant groups to calculate absolute 
diﬀ erences; otherwise the overall HR was used. 
Since two trials compared two chemotherapy 
regimens with one control group,13,14 we compared every 
treatment group with the control group and analysed as 
separate trial comparisons in diﬀ erent chemotherapy 
categories. However, to avoid double-counting the 
control groups in the overall and subgroup analyses, 
the treatment groups were combined and compared 
with the relevant control group. For other trials that 
belonged in diﬀ erent chemotherapy categories15 or 
diﬀ erent meta-analyses,16–18 or both,19,20 we compared 
relevant patients from the treatment group with the 
corresponding patients in the control group, and 
analysed them as separate trial comparisons. This 
method of analysis provides a greater number of trial 
comparisons than there are trials.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
Years of 
accrual
Number of 
patients
Country Drug used (dose per cycle [mg/m²]) Number of cycles Stage Extent of 
resection
(Continued from previous page)
With tegafur and uracil/tegafur
Platinum+vinca alkaloid+tegafur and uracil/tegafur
SGACLC ACTLC129 1982–85 306 Japan Cisplatin (0·08 mg/kg), mitomycin (2 mg/kg); tegafur (12 mg/kg) 10; daily treatment >6 months NK NK
OLCSG1c20 1983–88 28* Japan Cisplatin (80); tegafur (600–800 total) 1; daily treatment >1 year II Complete
SGACLC ACTLC233 1985–87 332 Japan Cisplatin (66), doxorubicin (26); tegafur and uracil (8 mg/kg) 1; daily treatment >6 months I–III Complete and 
incomplete
WJSG2 (1+3)13 1985–89 215* Japan Cisplatin (50); vindesine (2–3 mg/kg); tegafur and uracil (400) 1; 3; daily treatment for 1 year I–III Complete
WJSG335 1988–89 225 Japan Cisplatin (80), vindesine (2–3; once or twice), mitomycin (8); tegafur 
and uracil (400 total)
2; daily treatment for 1 year I–II Complete
Xu34 1989–92 70 China Cisplatin (100), cyclophosphamide (300), vincristine (1·4), doxorubicin 
(50), lomustine (50); then oral tegafur (600–900 total)
4; daily treatment for 1 year I–III Complete
ACTLC4a14 1992–95 104* Japan Cisplatin (80); vindesine (6); tegafur and uracil (400) 1; 2; daily treatment for 2 years I Complete
OLCSG2b15 1992–94 95* Japan Cisplatin (80), vindesine (6); tegafur and uracil (400 total) 2; daily treatment for 1 year II–III Complete
Tegafur and uracil/tegafur+other agent
OLSCG1b20 1982–86 83* Japan Doxorubicin (100), mitomycin (20); tegafur (600–800); followed by 
tegafur (600–800)
3; daily treatment; daily 
treatment >1 year
II–III Complete and 
incomplete
Tegafur and uracil/tegafur
OLCSG1a20 1982–88 321 Japan Tegafur (600–800 total) Daily treatment >1 year I Complete
WJSG2 (2+3)13 1985–88 208* Japan Tegafur and uracil (400) Daily treatment for 1 year I–III Complete
WJSG440 1991–94 367 Japan Tegafur and uracil (400 total) Daily treatment for 1 year I–II Complete
NJSGLCS37 1992–94 219 Japan Tegafur and uracil (260 total or 400 total) Daily treatment for 2 years I–II Complete
OLCSG2a15 1992–94 172* Japan Tegafur and uracil (400 total) Daily treatment for 1 year I Complete
ACTLC4b14 1992–95 104* Japan Tegafur and uracil (400 total) Daily treatment for 2 years I Complete
JLCRG38 1994–97 999 Japan Tegafur and uracil (250 total) Daily treatment for 2 years I Complete and 
incomplete
NK=not known. LCSG=Lung Cancer Study Group. FLCSG=Finnish Lung Cancer Study Group. IPCR=Institute of Pulmonary Cancer Research, Chiba. JLCSSG=Japan Lung Cancer Surgical Study Group. ALPI=Adjuvant 
Lung Cancer Project Italy. JCOG=Japan Clinical Oncology Group. ANITA=Adjuvant Navelbine International Trialist Association. IALT=International Adjuvant Lung Trial. BLT=Big Lung Trial. CALGB=Cancer and 
Leukemia Group B. OLCSG=Osaka Lung Cancer Study Group. SGACLC=Study Group of Adjuvant Chemotherapy for Lung Cancer. WJSG=West Japan Study Group for Lung Cancer Surgery. ACTLC=Study Group of 
Adjuvant Chemotherapy for Lung Cancer. NJSGLCS=North-east Japan Study Group for Lung Cancer. JLCRG=Japan Lung Cancer Research Group. *Only patients relevant to the particular meta-analysis and/or 
chemotherapy category. 
Table 1: Characteristics of trials of surgery plus chemotherapy versus surgery
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Figure 1: Eﬀ ect of surgery (S) and chemotherapy (CT) versus surgery on survival, by type of chemotherapy  
Every trial is represented by a square, the center of which denotes the hazard ratio (HR) for that trial comparison with the horizontal lines showing the 95% and 99% CIs. The size of the square is 
directly proportional to the amount of information contributed by the trial. The open diamonds represent pooled HRs for the trial groups, with the centre denoting the HR and the extremities the 
95% CI. The black diamond gives the pooled hazard ratio from the ﬁ xed eﬀ ect model, without double counting the control groups of the three-grouped trials WJSG2 and ACTLC4. The centre of this 
diamond denotes the HR and the extremities the 95% CI. The control groups of the three-grouped trials WJSG2 and ACTLC4 are included only once in the total events and patients and in the overall 
analysis. O–E=observed minus expected. IPCR=Institute of Pulmonary Cancer Research, Chiba. JLCSSG=Japan Lung Cancer Surgical Study Group. ALPI=Adjuvant Lung Cancer Project. 
IALT=International Adjuvant Lung Trial. BLT=Big Lung Trial. JCOG=Japan Clinical Oncology Group. ANITA=Adjuvant Navelbine International Trialist Association. CALGB=Cancer and Leukemia Group 
B. LCSG=Lung Cancer Study Group. FLCSG=Finnish Lung Cancer Study Group. SGACLC=Study Group of Adjuvant Chemotherapy for Lung Cancer. OLCSG=Osaka Lung Cancer Study Group. 
WJSG=West Japan Study Group for Lung Cancer Surgery. ACTLC=Study Group of Adjuvant Chemotherapy for Lung Cancer. NJSGLCS=North-east Japan Study Group for Lung Cancer. JLCRG=Japan 
Lung Cancer Research Group.  
S+CT 
Number events/ number entered
S alone
O–E    Variance HR (ﬁxed) HR (95% CI); p value
Heterogeneity: χ2=32·23, df=31, p=0·40, I2=4%
Interaction: χ2=12·25, df=6, p=0·06
Interaction (without OLCSG1B): χ2=6·06, df=5, p=0·30    
Platinum+vinca alkaloid/etoposide
 IPCR Chiba28
 JLCSSG31
 Mineo36
 Park141
 Park243
 ALPI116
 IALT118
 BLT119
 JCOG 930439
Subtotal
Platinum+vinorelbine
 ANITA117
 JBR.1042
 IALT218
 BLT219
Subtotal
Platinum+taxane
 CALGB 963344
Subtotal
Other platinum regimens
 LCSG 80130
 FLCSG145
 LCSG 85332
 BLT319
Subtotal
Platinum+vinca alkaloid+tegafur 
and uracil/tegafur 
 SGACLC ACTLC129
 OLCSG1c20
 SGACLC ACTLC233
 WJSG2 (1+3)13
 WJSG335
 Xu34
 ACTLC4a14
 OLCSG2b15
Subtotal
Tegafur and uracil/tegafur 
+other agent
 OLCSG1b20
Subtotal
 Tegafur and uracil/tegafur 
 OLSCG1a20
 WJSG2 (2+3)13
 WJSG440
 NJSGLCS37
 OLCSG2a15
 ACTLC4b14
 JLCRG38
Subtotal
Total
 11/15
 59/111
 14/33
 17/59
 37/53
 143/310
 235/499
 34/69
 33/59
 583/1208
 
 102/231
 86/242
 55/149
 15/37
 258/659
 
 78/173
 78/173
 
 66/140
 20/54
 29/94
 34/56
 149/344
 
 
 68/154
 5/12
 64/165
 44/115
 27/109
 19/35
 10/52
 28/47
 265/689
 
 
 27/41
 27/41
 
 30/163
 38/108
 38/176
 24/109
 20/85
 17/52
 67/498
 234/1191
 
 1594/4305
 7/14
 52/98
 21/33
 23/59
 43/55
 144/308
 243/502
 32/67
 35/60
 600/1196
 
 113/232
 111/240
 61/145
 15/28
 300/645
 
 93/171
 93/171
 
 71/143
 30/56
 32/94
 34/62
 167/355
 
 
 75/152
 7/16
 68/167
 49/100
 40/116
 26/35
 18/52
 28/48
 311/686
 
 
 21/42
 21/42
 
 28/158
 49/100
 56/191
 27/110
 35/87
 18/52
 91/501
 304/1199
 
 1729/4142
 1·33
 0·98
 –5·79
 –4·15
 –4·10
 0·83
 –7·96
 0·51
 –0·43
 –18·77
 
 –3·31
 –16·64
 –4·19
 –3·13
 –27·26
 
 –10·91
 –10·91
 
 –1·81
 –7·79
 –1·65
 3·21
 –8·04
 
 
 –7·09
 –0·19
 –4·80
 –7·66
 –6·01
 –4·67
 –5·22
 2·38
 –33·25
 
 
 6·59
 6·59
 
 –0·09
 –9·79
 –5·87
 –1·37
 –7·44
 –0·58
 –11·72
 –36·85
 
 –120·42
0·94 (0·84–1·05); p=0·273 
0·82 (0·70–0·97); p=0·021 
0·77 (0·57–1·05); p=0·094 
0·90 (0·72–1·13); p=0·363 
0·79 (0·67–0·93); p=0·005 
1·79 (1·00–3·20); p=0·050 
0·76 (0·64–0·90); p=0·001
0·86 (0·81–0·92); p<0·0001 
 4·07
 27·38
 8·51
 9·95
 19·87
 71·37
 119·34
 16·34
 16·94
 293·78
 
 53·68
 49·07
 28·96
 7·01
 138·71
 
 42·59
 42·59
 
 34·21
 12·21
 15·22
 16·43
 78·07
 
 
 35·62
 2·93
 32·88
 22·94
 16·74
 11·18
 6·92
 13·87
 143·07
 
 
 11·36
 11·36
 
 14·47
 21·49
 23·38
 12·73
 13·73
 8·75
 39·49
 134·04
 
 818·03
0·1 0·2 0·5 1 2 5 10
S+CT better S alone better 
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writing of the report. The corresponding authors had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
For the meta-analysis of surgery and chemotherapy 
versus surgery, we identiﬁ ed 35 eligible trials, of which 
26 were included: nine from the previous meta-analysis 
done in 1995, and 17 additional trials. Nine trials could 
not be included because: data were not available for three 
published21–23 and two small unpublished trials (NCCTG 
852451, EORTC 08922), adequate contact with the 
investigators could not be established for two trials,24,25 
and two trials have only recently been presented.26,27 
Therefore, data from 26 published trials13–20,28–45 were 
included, allowing 34 trial comparisons (table 1). 
Platinum-based chemotherapy without a combination 
of tegafur and uracil or tegafur alone was used in 18 trial 
comparisons, and with tegafur and uracil or tegafur in 
eight (table 1). In all but one trial,44 cisplatin was the 
platinum agent. Tegafur and uracil or tegafur alone was 
used in combination with other agents in one trial 
comparison and alone in seven (table 1). Data for 
histology and stage were provided for all 34 trial 
comparisons, age and sex for 33, and performance status 
for 24 (webappendix p 2). Patients were mostly men with 
a median age of 61 years (range 18–84). They tended to 
have good performance status and tumours that were 
predominantly stage I–II adenocarcinomas or squamous 
cell carcinomas (webappendix p 2). The few patients with 
stage IIIB and IV tumours included—eg, because of 
misclassiﬁ cation at diagnosis—were combined with 
stage IIIA patients for analysis; this group is subsequently 
referred to as stage III. The median follow-up was 
5·5 years (IQR 4·4–6·6). 
Survival results for the ﬁ rst meta-analysis were based 
on 34 trial comparisons and 8447 patients (3323 deaths), 
representing 92% of patients who were randomly 
assigned. The results show a beneﬁ t of chemotherapy 
(HR 0·86, 95% CI 0·81–0·92, p<0·0001; ﬁ gure 1), with 
minimum heterogeneity (p=0·40, I²=4%). This ﬁ nding 
represents an absolute improvement of 4% (95% CI 
3–6) at 5 years, increasing survival from 60% to 64% 
(ﬁ gure 2). We noted a diﬀ erence in eﬀ ect by 
chemotherapy category (interaction p=0·06, ﬁ gure 1), 
largely driven by the result of the OLCSG1b trial20 that 
alone constituted the chemotherapy category for tegafur 
and uracil or tegafur plus other agent. A sensitivity 
analysis excluding this trial did not suggest that this 
drug regimen aﬀ ects the eﬀ ect of chemotherapy (data 
not shown; interaction p=0·30). 
In view of the diﬀ erences in the types of chemotherapy 
used over time and by geographical region, we grouped 
trial comparisons by these characteristics for exploratory 
analyses. We noted no clear evidence of a diﬀ erence in 
the eﬀ ect between trial comparisons included in the 
1995 meta-analysis, and those included since this time 
(interaction p=0·76), by accrual decade (interaction 
p=0·61), or by geographical region (North America, 
Europe, Asia; interaction p=0·25; data not shown). Trial 
comparisons using tegafur and uracil or tegafur all 
originated in Asia, and recruited more women 
(n=1293 of 3465 [37%]) and more patients with 
stage I tumours (3003/3673 [82%]) of adenocarcinoma 
histology (2505/3676 [68%]) than those that did not use 
tegafur and uracil or tegafur alone (1093/4745 [23%], 
2613/4727 [55%], 1910/4744 [40%], respectively). How-
ever, we recorded no clear evidence of a diﬀ erence in 
trea tment eﬀ ect between trial comparisons that did 
(3848 [45%]; HR 0·80, 95% CI 0·71–0·90) and those that 
did not (4751 [55%]; HR 0·89, 0·82–0·97) use tegafur 
and uracil or tegafur (overall HR 0·86, 0·81–0·92, 
interaction p=0·16; webappendix p 3), even when we 
excluded the OLCSG1b trial comparison20 (data not 
shown; interaction p=0·07).
We recorded no signiﬁ cant evidence (p≥0·10) that any 
patient subgroup deﬁ ned by age, sex, histology, 
performance status, or stage beneﬁ ted more or less 
from chemotherapy (webappendix p 4). However, 
because of the geographical diﬀ erences in the types of 
patients and chemotherapy used, we undertook 
exploratory subgroup analyses separately for trial 
comparisons using platinum, without tegafur and 
uracil or tegafur, and those using these drugs. 
Stage I disease was also split into IA and IB for all but 
four trials,15,29,33,41 which had to be excluded since this 
information was not available. 
For the platinum without tegafur and uracil or tegafur 
alone group, although there was no evidence of diﬀ erence 
in the eﬀ ect of chemotherapy between patients with good 
Figure 2: Simple (non-stratiﬁ ed) Kaplan-Meier curves for trials of surgery (S) and chemotherapy (CT) versus 
surgery alone and for trials of surgery and chemotherapy and radiotherapy (RT) versus surgery and 
radiotherapy
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and poor performance status (interaction p=0·30; 
ﬁ gure 3), we noted an increasing relative eﬀ ect of 
chemotherapy with improving performance status (trend 
p=0·002; ﬁ gure 3), which was consistent across trials 
(data not shown; p=0·32). However, a few patients had a 
poor performance status (ﬁ gure 3). The relative eﬀ ect of 
chemotherapy did not diﬀ er signiﬁ cantly by other patient 
subgroups, including stage (trend p=0·13; ﬁ gure 3). 
Therefore, application of the overall hazard ratio to 
survival in the control group by stage suggests absolute 
improvements in 5-year survival of 3% (95% CI 2–5) for 
stage IA (from 70% to 73%), 5% (2–7) for stage IB (from 
55% to 60%), 5% (3–8) for stage II (from 40% to 45%), 
and 5% (3–8) for stage III disease (from 30% to 35%). 
The suggested survival beneﬁ t of 3% for stage IA and the 
HR of 1·19 (95% CI 0·84–1·68) for that subgroup seemed 
to be contradictory. However, data are scarce for this 
group of patients, the CIs are very wide, and the result is 
not signiﬁ cant (p=0·33).
In the tegafur and uracil or tegafur alone group, we 
noted no clear diﬀ erence in the eﬀ ect of chemotherapy 
between patients with good or poor performance status 
(interaction p=0·49; ﬁ gure 3), but did record a suggestion 
of an increasing relative eﬀ ect of chemotherapy with 
worsening performance status (trend p=0·02; ﬁ gure 3). 
This trend varies substantially across trials (data not 
shown; p=0·01), and few patients had a poor performance 
status. We noted no signiﬁ cant diﬀ erence in the relative 
eﬀ ect of chemotherapy by age, sex, histology, or stage, 
and application of the overall HR gave absolute 
improvements in 5-year survival of 2% (95% CI 1–3) for 
stage IA (from 80% to 82%), 3% (1–4) for 
stage IB (from 75% to 78%), 5% (2–7) for stage II (from 
45% to 50%), and 5% (3–8) for stage III disease (from 
25% to 30%). 
Data for recurrence-free survival were available for 
18 trial comparisons (2519 events; 5379 patients) and 
data for locoregional (936 events; 5226 patients) and 
distant recurrence (1267 events; 5224 patients) for 
16 trial comparisons, mostly from newer trials of 
platinum-based chemotherapy without tegafur and 
uracil or tegafur alone. Results for recurrence-free 
survival (HR 0·83, 95% CI 0·77–0·90, p<0·0001), time 
to locoregional recurrence (0·75, 0·66–0·85, p<0·0001), 
and time to distant recurrence (0·80, 0·72–0·89, 
p=0·0007) all signiﬁ cantly favoured chemotherapy. 
Exclusion of the four trial comparisons that included 
tegafur and uracil or tegafur alone14,34,35,38 showed similar 
results (data not shown).
For the second meta-analysis of surgery plus 
radiotherapy and chemotherapy versus surgery plus 
radiotherapy, we identiﬁ ed 15 eligible trials, of which 
Figure 3: Exploratory analyses of the eﬀ ect of surgery (S) and chemotherapy (CT) versus surgery on survival, by use of tegafur plus uracil or tegafur and by 
stage and performance status
HR=hazard ratio. O–E=observed minus expected. PS=performance status. 
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12 were included: six from the previous meta-analysis 
in 1995 and six additional trials. Three could not be 
included because: data were not available for one trial,22 
and adequate contact with investigators could not be 
made for two trials.46,47 Therefore, nine published16–20,48–51 
and three unpublished (EORTC 08861, MDA DM 87045, 
FLCSG3) trials were included, allowing 13 trial 
comparisons (table 2). 
In nine trial comparisons chemotherapy was given 
before radiotherapy, and in four it was given concurrently 
with radiotherapy (table 2). Platinum and a vinca alkaloid 
or etoposide was used in ten trial comparisons, platinum 
and tegafur and uracil  or tegafur alone in one, and other 
platinum regimens in two (table 2). Cisplatin was the 
sole platinum agent. Data for age, sex, and histology were 
supplied for all trial comparisons, stage and extent of 
resection for 12, and performance status for 11 
(webappendix p 2). On the basis of these data, patients 
were mostly men, with good performance status, a 
median age of 59 years (range 27–81), and stage III, 
squamous carcinomas (webappendix p 2). The few 
patients with stage IV tumours were combined with 
stage III patients for analyses, and referred to as stage III. 
The median follow-up was 6·4 years (IQR 4·6–8·3). 
Survival analyses were based on 13 trial comparisons 
and 2660 patients (1909 deaths), representing 86% of 
patients who were randomly assigned. The results 
showed a clear beneﬁ t of chemotherapy (HR 0·88, 
95% CI 0·81–0·97, p=0·009; ﬁ gure 4), with little 
heterogeneity (p=0·95, I²=0%). This ﬁ nding represents 
an absolute beneﬁ t of 4% (95% CI 1–8) at 5 years, 
increasing survival from 29% to 33% (ﬁ gure 2). We 
recorded no evidence of a diﬀ erential eﬀ ect by 
chemotherapy category (interaction p=0·45; ﬁ gure 4) or 
the extent of resection achieved (interaction p=0·54; 
data not shown), although few patients had incom-
plete resections. Furthermore, an exploratory analysis 
suggests that the timing of chemotherapy in relation 
to radiotherapy is unimportant (chemotherapy 
before radiotherapy, concomitant chemoradiotherapy; 
interaction p=0·28; data not shown). 
The relative eﬀ ect of chemotherapy did not diﬀ er 
signiﬁ cantly by age, sex, histology, performance status, 
or stage (webappendix p 6). Data for recurrence-free 
Years of 
Accrual
Number of 
patients
Country Drug used (dose per cycle [mg/m²]) Number 
of cycles
RT dose (Gy)/fraction Stage Extent of 
resection
Without tegafur and uracil/tegafur 
Platinum+vinca alkaloid/etoposide
MSKCC 80-5351 1981–87 72 USA Cisplatin (120), vindesine (9) 4 46/NK; concomitant CT-RT III Complete and 
incomplete
GETCB 01CB8248 1982–86 267 France Cisplatin (75), doxorubicin (40), vincristine (1·2), lomustine 
(80 total) alternating with cyclophosphamide (600)
3 60–65/30–33; CT before RT I-III Complete and 
incomplete
EORTC 08861 
(unpublished)
1986–90 24 International Cisplatin (100), vindesine (6) 4 56/28; CT for 2 cycles then 
concomitant CT-RT
IIB–IIIA Complete
MDA DM 87045 
(unpublished)
1987–93 34 USA Cisplatin (50–100), etoposide (60–120), cyclophosphamide 
(300–600)
NK 50–60/25–33; CT before RT NK Incomplete
Int 011549 1991–97 488 USA Cisplatin (60), etoposide (360) 4 50·4/28; concomitant CT-RT II, IIIA Complete
ALPI216 1994–99 470* Italy Cisplatin (100), vindesine (6), mitomycin C (8) 3 50–54/25–27; CT before RT I–IIIA Complete
IALT318 1995–2001 366* International Cisplatin (80, 100, or 120) and vindesine (3; weekly then 
twice weekly) or vinblastine (8; weekly then twice weekly) 
or etoposide (300)
3 or 4 <60; CT before RT I–III Complete
BLT419 1995–2001 49* UK Cisplatin (50), mitomycin (6), vinblastine (6); or cisplatin 
(80), vindesine (6)
3 40–60/15–30; CT before RT I–III Complete and 
incomplete
Platinum+vinorelbine
ANITA217 1994–2000 377* International Cisplatin (100), vinorelbine (120) 4 45–60/23–30; CT before RT IB–IIIA Complete
IALT418 1995–2001 206* International Cisplatin (80,100, or 120), vinorelbine (30 weekly) 3 or 4 <60; CT before RT I–III Complete
Other platinum regimens
LCSG 79150 1979–85 172 USA, Canada Cisplatin (40), cyclophosphamide (400), doxorubicin (40) 6 40/10†; concomitant CT-RT for 
ﬁ rst 2 cycles
I-III Incomplete
FLCSG3 
(unpublished)
1982–87 86 Finland Cisplatin (40), cyclophosphamide (400), doxorubicin (40) 8 55/20†; 2 cycles of CT before RT I–III Incomplete
With tegafur and uracil/tegafur 
OLCSG1d20 1983–87 49 Japan Cisplatin (80), tegafur (600–800 given orally; daily 
treatment)
NK 50/25; CT before RT III Complete and 
incomplete
RT=radiotherapy. CT=chemotherapy. NK=not known. LCSG=Lung Cancer Study Group. MSKCC=Memorial Sloan Kettering Cancer Center. GETCB=Groupe d’Etude et de Traitement des Cancers Bronchiques. 
FLCSG=Finnish Lung Cancer Study Group. EORTC=European Organization for Research and Treatment of Cancer. MDA DM=MD Anderson Department of Medicine. Int=Intergroup. ALPI=Adjuvant Lung Cancer 
Project Italy. IALT=International Adjuvant Lung Trial. BLT=Big Lung Trial. ANITA=Adjuvant Navelbine International Trialist Association. OLCSG=Osaka Lung Cancer Study Group. *Only patients relevant to the 
particular meta-analysis and/or chemotherapy category. †Split-course radiotherapy.
Table 2: Characteristics of trials surgery plus radiotherapy and chemotherapy versus surgery plus radiotherapy
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survival, and locoregional and distant recurrence, were 
available for eight trial comparisons (2247 patients). 
Results for recurrence-free survival (1673 events, 
2247 patients; HR 0·85, 95% CI 0·77–0·93, p=0·0006), 
time to locoregional recurrence (533 events; 0·79, 
0·67–0·94, p=0·008), and time to distant recurrence 
(806 events; 0·75, 0·66–0·87, p<0·0001) all showed a 
signiﬁ cant beneﬁ t of chemotherapy. 
Discussion
Our results show a beneﬁ t of adjuvant chemotherapy 
after surgery, which has been already shown in some 
large trials but not in others (eg, ALPI15 and CALGB 
963343). They also show a beneﬁ t of chemotherapy in 
the presence of postoperative radiotherapy. The 
absolute survival improvements of 4% at 5 years are 
fairly modest, but might result in 10 000 more patients 
alive at 5 years.3 The results of the two meta-analyses 
are based on data from 47 comparisons in 33 trials and 
11 107 patients with non-small-cell lung cancer, which 
is more than three times that available in 1995.4 In 
these meta-analyses, we have an opportunity to bring 
together most trials undertaken during the past few 
decades, and to assess the eﬀ ectiveness of adjuvant 
chemotherapy in patients with non-small-cell lung 
cancer worldwide. 
Although we noted no signiﬁ cant diﬀ erence in eﬀ ect 
between chemotherapy categories in the ﬁ rst meta-
analysis, results for the trials that used older vinca 
alkaloids (vinblastine, vindesine, vincristine), etoposide, 
or other platinum combinations were somewhat 
uncertain, whereas trials using a combination of 
platinum and vinorelbine provided slightly more reliable 
evidence of beneﬁ t to inform present clinical practice 
(ﬁ gures 1 and 4). The results for chemotherapy with 
tegafur and uracil or tegafur alone are similar to those for 
platinum-based regimens. However, results come largely 
from older studies in Asian populations, which are 
increasingly showing diﬀ erences in their response to 
treatment,52 and so cannot be extrapolated to modern 
practice in non-Asian patients. A trial of tegafur and 
uracil or tegafur alone in patients with stage IA, 
adenocarcinoma from non-Asian countries would be 
beneﬁ cial in this context. Results of an ongoing trial 
might establish the relative merits of carboplatin-
paclitaxel and tegafur and uracil in Asian patients.53
Guidelines from Cancer Care Ontario and American 
Society of Clinical Oncology (ASCO)17–19,42,54 recommend 
that adjuvant cisplatin-based chemotherapy is given to 
patients with stage II and IIIA non-small-cell lung cancer. 
These guidelines state that evidence is insuﬃ  cient to 
make recommendations for patients with stage IA 
Figure 4: Eﬀ ect of surgery (S) and radiotherapy (RT) and chemotherapy (CT) versus surgery and radiotherapy on survival by type of chemotherapy
HR=hazard ratio. O–E=observed minus expected. MSKCC=Memorial Sloan Kettering Cancer Center. GETCB=Groupe d’Etude et de Traitement des Cancers Bronchiques. 
MDA DM=MD Anderson Department of Medicine. Int=Intergroup. ALPI=Adjuvant Lung Cancer Project Italy. IALT=International Adjuvant Lung Trial. BLT=Big Lung 
Trial. ANITA=Adjuvant Navelbine International Trialist Association. LCSG=Lung Cancer Study Group. FLCSG=Finnish Lung Cancer Study Group. OLCSG=Osaka Lung 
Cancer Study Group.
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disease, and one meta-analysis10 reported a signiﬁ cant 
decrease in the eﬀ ect of cisplatin-based chemotherapy by 
stage, largely driven by the stage IA result. This meta-
analysis does not show signiﬁ cant diﬀ erences in the 
eﬀ ect of platinum chemotherapy (without tegafur and 
uracil or tegafur alone) by stage or signiﬁ cantly poorer 
survival in patients with stage IA disease (ﬁ gure 3). The 
evidence in stage IA tumours remains scarce until results 
from further trials are available. 
The ASCO guidelines also state that none of the studies 
reviewed showed a signiﬁ cant beneﬁ t of adjuvant 
chemotherapy in patients with stage IB tumours. By 
contrast, our estimate of the eﬀ ect of platinum-based 
chemotherapy in patients with stage IB tumours is based 
on a substantial number of events and is similar to 
estimates for patients with stage II and III tumours 
(ﬁ gure 3). Since we did not collect data for tumour size, 
patients with larger stage IB tumours, who would be 
classed as stage II in the 7th edition of the TNM staging 
system55 and might achieve a greater beneﬁ t from 
chemotherapy,44 are potentially included. In the absence 
of comorbidities and contraindications to chemotherapy, 
adjuvant platinum-based chemotherapy should be 
considered for patients at high risk of recurrence—
ie, those with stage IB, II, or III disease. Whether 
cisplatin-based chemotherapy should be used in patients 
with stage IA disease remains uncertain, since the 
scarcity of data did not allow us to distinguish reliably 
between a beneﬁ t, a detriment, or no eﬀ ect.
Most patients had good performance status and the 
beneﬁ t was clear in this group. A small increasing eﬀ ect of 
platinum-based chemotherapy with better performance 
status was also apparent in this and another meta-analysis,10 
but was not conﬁ rmed in trials using tegafur and uracil  or 
tegafur alone or those that included postoperative 
radiotherapy. Nevertheless, these results could suggest 
cautious use of platinum-based chemotherapy in less ﬁ t 
patients. Despite the amount of data collected, some of the 
subgroup analyses lacked power.
The beneﬁ ts of adjuvant chemotherapy have been 
reported to be attenuated in long-term results;56,57 however, 
we do not have much data beyond 5 years. The potential 
beneﬁ t of chemotherapy should always be balanced with 
possible toxic eﬀ ects for the individual patient. We were 
unable to assess toxic eﬀ ects of treatment in this study. 
Moreover, extrapolation of the results to patients with 
comorbidities is uncertain because most of the patients 
included in these meta-analyses had mild or no 
comorbidities.
Addition of chemotherapy to surgery and postoperative 
radiotherapy gave a 4% improvement in 5-year survival 
from 29% to 33%. This increase does not seem to vary 
with the timing of chemotherapy in relation to 
radiotherapy, extent of surgery, or by patient subgroup 
(table 2, webappendix p 5). The lower survival rates than 
those in the surgery and chemotherapy meta-analysis are 
most likely because patients with stage III tumours 
predominate and the incomplete resection rate is higher 
(table 2). A previous meta-analysis58,59 has shown that 
postoperative radiotherapy has a detrimental eﬀ ect on 
survival, particularly for early stage tumours, but old 
radiotherapy techniques were used. This meta-analysis 
was not designed to study the eﬀ ect of postoperative 
radiotherapy, but has shown that the eﬀ ect of 
chemotherapy is similar irrespective of what locoregional 
treatment is used: surgery alone or surgery plus 
postoperative radiotherapy. Randomised trials are needed 
to assess whether modern radiotherapy is eﬀ ective as an 
adjuvant treatment.
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